« Return to News | R&D Trends | Drug Sponsors

WuXi Revenues Up 98%, Still Fall Short

Thursday, November 13, 2008 10:14 AM

WuXi Pharmatech released final third quarter earnings that reflected 98% revenue growth year-over-year but fell short of the company’s projected Q3 earnings.

Net revenues for the quarter were $67.5 million, down from the $74 million originally forecast. The Chinese contract research organization confirmed its most recent revised full-year revenue guidance of $260 million to $265 million. WuXi share prices dropped 5% to $7.42 in morning trading Thursday.

WuXi also announced this week the signing of a new three-year in vitro ADME collaboration agreement with Pfizer, and, last month, WuXi signed a new R&D collaboration agreement with Johnson & Johnson, expanding the already long-standing relationship between the two companies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 20

IRB consolidation trend continues, as private equity firm Audax buys majority stake in Chesapeake

Quintiles, Merck Serono ink exclusive partnership

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.